By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ocata Therapeutics (Formerly Known As Advanced Cell Technology) 

33 Locke Drive

Marlborough  Massachusetts   01752  U.S.A.
Phone: 580-756-1212 Fax: 580-229-2333


Company News
Astellas (ALPMY) Announces Results Of Tender Offer To Acquire All Outstanding Shares Of Ocata And Changes To Subsidiaries 2/10/2016 7:57:15 AM
Astellas (ALPMY) Extends Tender Offer To Acquire All Outstanding Shares Of Ocata 1/22/2016 7:33:48 AM
Ocata Reports The Publication Of Data About The Generation Of Corneal Endothelial Cells From Human Pluripotent Stem Cells 12/28/2015 9:37:52 AM
Ocata’s Hemangio-Derived Mesenchymal Cells Preserve Kidney Function And Extend Lifespan In Preclinical Model Of Lupus Nephritis 12/3/2015 10:02:13 AM
Astellas (ALPMY) Snaps Up Stem Cell Pioneer Ocata in $379 Million Deal 11/10/2015 6:07:58 AM
Ocata Therapeutics To Host Conference Call And Webcast To Provide Corporate Update For The Third Quarter 11/9/2015 11:37:47 AM
Ocata Therapeutics To Present At Ladenburg Thalmann 2015 Healthcare Conference 9/23/2015 12:31:40 PM
Canine Patients Treated With Ocata Therapeutics’s Hemangio-Derived Mesenchymal Cells (HMC) Achieve Remission In A Model Of Crohn’s Disease 9/22/2015 10:34:50 AM
First Patient Enrolled In Ocata Therapeutics’ Phase II Study For Dry AMD 9/8/2015 11:28:53 AM
Dr. Robert Lanza, Chief Scientific Officer Of Ocata Therapeutics Awarded The Honor Of iPSC Industry Influencer 9/3/2015 10:49:43 AM